Assessment of Thyroid Dysfunction in Patients Undergoing Haemodialysis at Sohag University Hospital

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age13-80
SponsorSohag University

About this trial

Thyroid dysfunction is a prevalent endocrine disorder that significantly impacts the health of patients with chronic kidney disease (CKD), particularly those undergoing dialysis. The prevalence of thyroid dysfunction in dialysis patients has been reported to range from 20% to 60%, highlighting the need for routine screening and management in this vulnerable group (Kuo et al., 2024). Thyroid hormones play a crucial role in regulating various physiological processes, and their dysregulation can lead to complications such as cardiovascular disease, anemia, and impaired quality of life, which are particularly concerning in the dialysis population (Smith et al., 2024).

The relationship between CKD and thyroid dysfunction is complex and multifactorial. Uremic toxins can interfere with the hypothalamic-pituitary-thyroid axis, leading to alterations in thyroid hormone production and metabolism. Recent studies have shown that inflammation and oxidative stress associated with CKD can further exacerbate thyroid dysfunction (Johnson et al., 2024). Understanding these mechanisms is essential for developing effective management strategies for thyroid health in dialysis patients.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Adults aged 18 years and older.

Patients diagnosed with end-stage renal disease (ESRD) on regular hemodialysis for at least 3 months.

Disqualifiers

Known Thyroid Disorders: Patients with a history of thyroid disease (e.g., hypothyroidism, hyperthyroidism) prior to starting dialysis.

Recent Thyroid Treatment: Patients who have received treatment for thyroid dysfunction (e.g., thyroid hormone replacement, antithyroid medications) within the last six months.

Patients with acute kidney injury (AKI) or those who are not on regular dialysis.

Pregnant or lactating women.

Trial population

patients undergoing hemodialysis in sohag university hospital

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

  • Thyroid profile

    Diagnostic test

    Thyroid dysfunction in patients undergoing hemogdialysis in sohag university hospital

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Number of Participants With Thyroid Dysfunction Diagnosed by Serum TSH, Free T3, and Free T4 Levels

Diagnosis will be classified as: Hypothyroidism Subclinical hypothyroidism Hyperthyroidism

Time frame
Up to 6 months from enrollment

Secondary outcomes

1

Number of Participants With Thyroid Dysfunction Stratified by Dialysis Duration and Ultrafiltration Rate

Number of Participants With Thyroid Dysfunction Stratified by Dialysis Duration and Ultrafiltration Rate Dialysis duration recorded in months Ultrafiltration rate recorded in mL/kg/hour Thyroid dysfunction diagnosed by TSH, free T3, and free T4 levels

Time frame
Up to 6 months from enrollment

Other outcomes

1

Number of Participants With Thyroid Dysfunction by Underlying Cause of Kidney Disease

Number of Participants With Thyroid Dysfunction by Underlying Cause of Kidney Disease Kidney disease categories: Diabetic nephropathy Hypertensive nephrosclerosis Chronic glomerulonephritis Thyroid dysfunction diagnosed by serum TSH, free T3, and free T4

Time frame
Up to 6 months from enrollment

Sponsors and contacts

Click on the lead sponsor to view all of their trials.